Clinical Trial Update: GM-CSF as Adjuvant Therapy of Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GM-CSF as adjuvant therapy for malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Northern California Melanoma Center | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED